Synaptogenix Inc - ESG Rating & Company Profile powered by AI
The ESG rating covers seventeen UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Reduced Inequalities' and 'Partnerships for the Goals'. Comprehensive Sustainability analysis of Synaptogenix Inc are reached by registering for free. If you are employed by Synaptogenix Inc and you wish to use your Sustainability aseessment, please contact us.
Synaptogenix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 0.0, social score of 5.3 and governance score of 8.0.
4.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 868 | Trevena Inc | 4.5 | High |
| 868 | Urogen Pharma Ltd | 4.5 | High |
| 910 | Synaptogenix Inc | 4.4 | High |
| 910 | CanBas Co Ltd | 4.4 | High |
| 910 | CNS Pharmaceuticals Inc | 4.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Synaptogenix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Synaptogenix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Synaptogenix Inc report the average age of the workforce?
Sign up for free to unlockDoes Synaptogenix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Synaptogenix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Synaptogenix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Synaptogenix Inc offer flexible work?
Sign up for free to unlockDoes Synaptogenix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Synaptogenix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Synaptogenix Inc conduct supply chain audits?
Sign up for free to unlockDoes Synaptogenix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Synaptogenix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Synaptogenix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Synaptogenix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Synaptogenix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Synaptogenix Inc disclose water use targets?
Sign up for free to unlockDoes Synaptogenix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Synaptogenix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Synaptogenix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Synaptogenix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Synaptogenix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Synaptogenix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Synaptogenix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Synaptogenix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Synaptogenix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Synaptogenix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Synaptogenix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Synaptogenix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Synaptogenix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Synaptogenix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Synaptogenix Inc disclose its waste policy?
Sign up for free to unlockDoes Synaptogenix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Synaptogenix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Synaptogenix Inc disclose energy use targets?
Sign up for free to unlockDoes Synaptogenix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Synaptogenix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Synaptogenix Inc
These potential risks are based on the size, segment and geographies of the company.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.